Alkaptonuria (AKU) + hereditary tyrosinemias

What changes during this transition

Alkaptonuria (AKU) is an autosomal recessive inborn error of tyrosine catabolism caused by biallelic mutations in HGD (homogentisate 1,2-dioxygenase, chromosome 3q13.33). Loss of HGD activity allows homogentisic acid (HGA) to accumulate; HGA oxidizes to benzoquinone acetate and deposits as ochronotic pigment in connective tissue. The disease was **first described by Archibald Garrod in 1902 as the founding example of 'inborn error of metabolism'** — the moment Mendelian inheritance was applied to a human disease for the first time. That historical position is editorially honorable in any AKU conversation. The childhood presentation is black-staining urine on exposure to air (alkaline oxidation of HGA), often noticed in the diaper era. The adult presentation — ochronosis (slate-blue/black pigmentation of cartilage, sclera, ear cartilage, and skin) and ochronotic arthropathy with severe destructive arthritis of the lumbar and cervical spine first, then large joints, often driving multiple joint replacements; aortic and mitral valve calcification and ochronotic coronary artery disease affecting roughly 80% of patients by age 60; and kidney stones from HGA crystallization — usually develops over decades. **AKU is often diagnosed late, in adulthood, when ochronotic arthropathy finally presents**, which means a substantial fraction of the patient experience is reconstructing what a destructive joint and cardiac disease meant in retrospect. **Slovak Republic and Dominican Republic founder populations** carry the highest known AKU prevalence and have anchored most of the cohort-based natural-history work. The broader hereditary tyrosinemias share a tyrosine-catabolism family. **Hereditary tyrosinemia type I (HT-1)** is caused by FAH (fumarylacetoacetate hydrolase) mutations; before treatment it caused a fatal pediatric liver and kidney disease, and the **Quebec Saguenay-Lac-Saint-Jean founder population** carries the highest known global prevalence. **HT-2 (Richner-Hanhart syndrome)** is caused by TAT mutations with oculocutaneous presentation. **HT-3** is caused by HPD mutations and is rare. The transformative therapy across the family is **nitisinone (Orfadyn, Sobi)**, an HPPD inhibitor that acts upstream of the metabolic block — reducing HGA production in AKU and toxic upstream metabolites in HT-1. Nitisinone was **FDA-approved in 2002 for HT-1**, converting what had been a fatal pediatric disease into a manageable chronic condition, and **FDA-approved in October 2020 for alkaptonuria** after the SONIA-2 European DevelopAKUre trial demonstrated reduction in ochronotic progression — 118 years after Garrod's founding description. Both approvals are genuinely transformative for their respective patient communities. **Dietary tyrosine and phenylalanine restriction** is the load-bearing adjunct to nitisinone, preventing the HPPD-inhibition hypertyrosinemia that drives corneal and skin complications above roughly 700-800 µmol/L plasma tyrosine. Joint replacement and cardiac valve surgery are common in advanced AKU. The **AKU Society (UK, akusociety.org)** is the main international patient organization, the **Genetic Alkaptonuria Network** supports family connections, the **DevelopAKUre European consortium** (Cardiff-coordinated) is the international research network that produced SONIA-1, SONIA-2, and SOFIA, and the **UK Royal Liverpool National AKU Centre** serves as a primary specialty center. Community peptide framing reaches this axis through several distinct paths. BPC-157's tissue-repair marketing collides with the reality that ochronotic cartilage destruction is pigment-mediated and not a repair deficit BPC-157 has any preclinical signal against. NMN's general-aging framing meets an aging post-nitisinone AKU cohort with no characterization data. The GH-axis trio extends the narrow real precedent of somatropin in confirmed pediatric GHD in HT-1 (Quebec cohort) into community GHRH/GHRP protocols that are not interchangeable; tesamorelin's HIV-lipodystrophy FDA label does not propagate to any inborn error of metabolism (Rule 6 sharpest in this batch). Semaglutide is appropriate for adult-AKU cardiovascular and metabolic comorbidities but requires coordination with the metabolic team because GI side effects can disrupt protein-substitute adherence and shift plasma tyrosine control on nitisinone. Ninety-fourth deliberate non-elevation.